As Kiran Mazumdar-Shaw plans succession, Biocon bets on biosimilars and obesity drugs for next growth wave

With Claire Mazumdar named successor, Biocon says years of investment in biosimilars and GLP-1 therapies are beginning to translate into scale, margins and global market share.

Go to News Site